Ipsen's Stock Rebounds to €158.70 After Plunge, Up 54% Over the Year

Technical Rebound at the Lower Bollinger Band Following Monday's Plunge

Ipsen's stock gains 2.45% to €158.70 after its previous day's plunge, which broke its 20 and 50-day moving averages. The price moves at the lower end of the Bollinger Bands (10% of the amplitude), very close to the lower boundary at €157.11. The RSI at 36 indicates the exhaustion of selling in recent sessions. However, the stock remains below its 20-day moving average (€164.74) and 50-day moving average (€160.95). The support at €154.90, corresponding to the last closing price, was not breached. The stock is still significantly above its 200-day average (€134.09), a difference of 18.35%. Over the week, the stock has lost 3.53%, but still shows a year-on-year gain of 54.08%.

Busy Clinical Schedule and Valuation Half as Expensive as the Sector

Fundamentally, Ipsen has made several recent announcements. The group received European approval for Ojemda in pediatric oncology on April 22, and will present phase II data on corabotase at the SCALE symposium on May 16. On April 23, the group reported a Q1 2026 revenue increase of 22.6% at constant exchange rates, and confirmed its annual guidance (growth over 13%). In governance matters, Karen Witts stepped down from her director role at the end of the May 13 AGM, with Pascal Touchon serving as interim at the audit committee. In April, Beech Tree also obtained a waiver from the obligation to make a public offer. Based on the consensus of eight analysts, the stock is trading at about 11.5 times the earnings expected for the current fiscal year, compared to 22.3 times on average for the Health Care sector. The next key date on the financial calendar is the publication of the first half 2026 results on July 30.